Population-based Study of First Hospitalizations for Heart Failure and the Interaction Between Readmissions and Survival

Fernández-Gassó, Lucía; Hernando-Arizaleta, Lauro; Palomar-Rodríguez, Joaquín A.; Abellán-Pérez, María Victoria; Hernández-Vicente, Álvaro; Pascual-Figal, Domingo A.

doi:10.1016/j.rec.2018.08.014

Cited by 10 publications

(9 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…During the first year after diagnosis of HF, approximately half of the patients may be expected to be hospitalized at least once. In addition, readmission rates are high [7,[30][31][32]. Importantly, it has been reported that in Spain, rates of first hospitalization due to HF continue to increase, with high mortality [32].…”

Section: Discussionmentioning

confidence: 99%

Costs and healthcare utilisation of patients with heart failure in Spain

Cervantes

Varela

Palacios

et al. 2020

BMC Health Serv Res

View full text Add to dashboard Cite

Background Increasing the knowledge about heart failure (HF) costs and their determinants is important to ascertain how HF management can be optimized, leading to a significant decrease of HF costs. This study evaluated the cumulative costs and healthcare utilisation in HF patients in Spain. Methods Observational, retrospective, population-based study using BIG-PAC database, which included data from specialized and primary care of people ≥18 years, from seven autonomous communities in Spain, who received care for HF between 2015 and 2019. The healthcare and medication costs were summarized on a yearly basis starting from the index date (1st January 2015), and then cumulatively until 2019. Results We identified 17,163 patients with HF (year 2015: mean age 77.3 ± 11.8 years, 53.5% men, 51.7% systolic HF, 43.6% on NYHA functional class II). During the 2015–2019 period, total HF associated costs reached 15,373 Euros per person, being cardiovascular disease hospitalizations the most important determinant (75.8%), particularly HF hospitalizations (51.0%). Total medication cost accounted for 7.0% of the total cost. During this period, there was a progressive decrease of cardiovascular disease hospital costs per year (from 2834 Euros in 2015 to 2146 Euros in 2019, P < 0.001), as well as cardiovascular and diabetic medication costs. Conclusions During the 2015–2019 period, costs of HF patients in Spain were substantial, being HF hospitalizations the most important determinant. Medication costs represented only a small proportion of total costs. Improving HF management, particularly through the use of drugs that reduce HF hospitalization may be helpful to reduce HF burden.

show abstract

Section: Discussionmentioning

confidence: 99%

Costs and healthcare utilisation of patients with heart failure in Spain

Cervantes

Varela

Palacios

et al. 2020

BMC Health Serv Res

View full text Add to dashboard Cite

show abstract

“…HF is associated with several symptoms (e.g. shortness of breath and fatigue) that impair quality of life and is also associated with high mortality rates, recurrent hospitalizations, and high direct and indirect costs …”

Section: Introductionmentioning

confidence: 99%

Cognitive impairment in patients with heart failure: an international study

et al. 2019

View full text Add to dashboard Cite

Aims Cognitive impairment (CI) in heart failure (HF) patients has mostly been studied in single countries in specific health care settings. Sociodemographic and clinical predictors of the global CI and CI dimensions are still unclear. We described CI in a diverse HF population recruited in several countries and in different health care settings and investigated sociodemographic and clinical factors associated with the global and specific CI dimensions in HF patients. Methods and results A secondary analysis from the baseline data of the Wii‐HF trial. Patients (n = 605) were enrolled in Sweden, Italy, Israel, The Netherlands, Germany, and the United States. We used the Montreal Cognitive Assessment to evaluate CI and the 6 minute walk test (6MWT) to measure exercise capacity. Patients were on average 67 years old (SD, 12), and 86% were in New York Heart Association Class II and III. The mean Montreal Cognitive Assessment score was 24 (SD, 4), and 67% of patients had at least a mild CI. The item evaluating short‐term memory had a considerable proportion of low scoring patients (28.1%). Worse CI was associated with patients' older age, lower education, and lower 6MWT scores (R2 = 0.27). CI dimension scores were differently associated with specific clinical and demographic variables, but the 6MWT scores were associated with five out of seven CI dimension scores. Conclusions CI is an important problem in HF patients, with specific challenges in regard to memory. Exercise capacity is a modifiable factor that could be improved in HF patients with the potential to improve cognition and other outcomes in this population.

show abstract

“…During the rst year after diagnosis of HF, approximately half of the patients may be expected to be hospitalized at least once. In addition, readmission rates are high [7,[30][31][32]. Importantly, it has been reported that in Spain, rates of rst hospitalization due to HF continue to increase, with high mortality [32].…”

Section: Discussionmentioning

confidence: 99%

Costs and healthcare utilisation of patients with heart failure in Spain

Cervantes

Varela

Palacios³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Increasing the knowledge about heart failure (HF) costs and their determinants is important to ascertain how HF management can be optimized, leading to a significant decrease of HF costs. This study evaluated the cumulative costs and healthcare utilisation in HF patients in Spain. Methods: Observational, retrospective, population-based study using BIG-PAC database, which included data from specialized and primary care of people ≥18 years, from seven autonomous communities in Spain, who received care for HF between 2015 and 2019. The healthcare and medication costs were summarized on a yearly basis starting from the index date (1st January 2015), and then cumulatively until 2019.Results: We identified 17,163 patients with HF (year 2015: mean age 77.3±11.8 years, 53.5% men, 51.7% systolic HF, 43.6% on NYHA functional class II). During the 2015-2019 period, total HF associated costs reached 15,373 Euros per person, being cardiovascular disease hospitalizations the most important determinant (75.8%), particularly HF hospitalizations (51.0%). Total medication cost accounted for 7.0% of the total cost. During this period, there was a progressive decrease of cardiovascular disease hospital costs per year (from 2,834 Euros in 2015 to 2,146 Euros in 2019, P<0.001), as well as cardiovascular and diabetic medication costs. Conclusions: During the 2015-2019 period, costs of HF patients in Spain were substantial, being HF hospitalizations the most important determinant. Medication costs represented only a small proportion of total costs. Improving HF management, particularly through the use of drugs that reduce HF hospitalization may be helpful to reduce HF burden.

show abstract

Population-based Study of First Hospitalizations for Heart Failure and the Interaction Between Readmissions and Survival

Cited by 10 publications

References 19 publications

Costs and healthcare utilisation of patients with heart failure in Spain

Costs and healthcare utilisation of patients with heart failure in Spain

Cognitive impairment in patients with heart failure: an international study

Costs and healthcare utilisation of patients with heart failure in Spain

Contact Info

Product

Resources

About